Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

The effect of unilateral subthalamic nucleus deep brain stimulation on depression in Parkinson's disease.

Birchall EL, Walker HC, Cutter G, Guthrie S, Joop A, Memon RA, Watts RL, Standaert DG, Amara AW.

Brain Stimul. 2017 May - Jun;10(3):651-656. doi: 10.1016/j.brs.2016.12.014. Epub 2016 Dec 27.

2.

Spatial topographies of unilateral subthalamic nucleus deep brain stimulation efficacy for ipsilateral, contralateral, midline, and total Parkinson disease motor symptoms.

Shenai MB, Romeo A, Walker HC, Guthrie S, Watts RL, Guthrie BL.

Neurosurgery. 2015 Mar;11 Suppl 2:80-8; discussion 88. doi: 10.1227/NEU.0000000000000613.

PMID:
25599197
3.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K.

JAMA Neurol. 2014 May;71(5):543-52. doi: 10.1001/jamaneurol.2014.131.

PMID:
24664227
4.

Novel, high-intensity exercise prescription improves muscle mass, mitochondrial function, and physical capacity in individuals with Parkinson's disease.

Kelly NA, Ford MP, Standaert DG, Watts RL, Bickel CS, Moellering DR, Tuggle SC, Williams JY, Lieb L, Windham ST, Bamman MM.

J Appl Physiol (1985). 2014 Mar 1;116(5):582-92. doi: 10.1152/japplphysiol.01277.2013. Epub 2014 Jan 9.

5.

Effects of deep brain stimulation frequency on bradykinesia of Parkinson's disease.

Huang H, Watts RL, Montgomery EB Jr.

Mov Disord. 2014 Feb;29(2):203-6. doi: 10.1002/mds.25773. Epub 2014 Jan 2.

PMID:
24395752
6.

The relationship between clinical phenotype and early staged bilateral deep brain stimulation in Parkinson disease.

Sung VW, Watts RL, Schrandt CJ, Guthrie S, Wang D, Amara AW, Guthrie BL, Walker HC.

J Neurosurg. 2013 Dec;119(6):1530-6. doi: 10.3171/2013.8.JNS122025. Epub 2013 Sep 27.

7.

Impaired financial abilities in Parkinson's disease patients with mild cognitive impairment and dementia.

Martin RC, Triebel KL, Kennedy RE, Nicholas AP, Watts RL, Stover NP, Brandon M, Marson DC.

Parkinsonism Relat Disord. 2013 Nov;19(11):986-90. doi: 10.1016/j.parkreldis.2013.06.017. Epub 2013 Jul 27.

8.

Unveiling interactions among mitochondria, caspase-like proteases, and the actin cytoskeleton during plant programmed cell death (PCD).

Lord CE, Dauphinee AN, Watts RL, Gunawardena AH.

PLoS One. 2013;8(3):e57110. doi: 10.1371/journal.pone.0057110. Epub 2013 Mar 6.

9.

Short latency activation of cortex by clinically effective thalamic brain stimulation for tremor.

Walker HC, Huang H, Gonzalez CL, Bryant JE, Killen J, Knowlton RC, Montgomery EB Jr, Cutter GC, Yildirim A, Guthrie BL, Watts RL.

Mov Disord. 2012 Sep 15;27(11):1404-12. doi: 10.1002/mds.25137. Epub 2012 Aug 27.

10.

Short latency activation of cortex during clinically effective subthalamic deep brain stimulation for Parkinson's disease.

Walker HC, Huang H, Gonzalez CL, Bryant JE, Killen J, Cutter GR, Knowlton RC, Montgomery EB, Guthrie BL, Watts RL.

Mov Disord. 2012 Jun;27(7):864-73. doi: 10.1002/mds.25025. Epub 2012 May 30.

11.

Comparison of weight changes following unilateral and staged bilateral STN DBS for advanced PD.

Lee EM, Kurundkar A, Cutter GR, Huang H, Guthrie BL, Watts RL, Walker HC.

Brain Behav. 2011 Sep;1(1):12-8. doi: 10.1002/brb3.9.

12.

Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson's disease.

Amara AW, Standaert DG, Guthrie S, Cutter G, Watts RL, Walker HC.

Parkinsonism Relat Disord. 2012 Jan;18(1):63-8. doi: 10.1016/j.parkreldis.2011.09.001. Epub 2011 Sep 15.

13.

High-frequency deep brain stimulation of the putamen improves bradykinesia in Parkinson's disease.

Montgomery EB Jr, Huang H, Walker HC, Guthrie BL, Watts RL.

Mov Disord. 2011 Oct;26(12):2232-8. doi: 10.1002/mds.23842. Epub 2011 Jun 28.

14.

Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial.

Gross RE, Watts RL, Hauser RA, Bakay RA, Reichmann H, von Kummer R, Ondo WG, Reissig E, Eisner W, Steiner-Schulze H, Siedentop H, Fichte K, Hong W, Cornfeldt M, Beebe K, Sandbrink R; Spheramine Investigational Group.

Lancet Neurol. 2011 Jun;10(6):509-19. doi: 10.1016/S1474-4422(11)70097-7. Epub 2011 May 10.

PMID:
21565557
15.

The effects of deep brain stimulation on sleep in Parkinson's disease.

Amara AW, Watts RL, Walker HC.

Ther Adv Neurol Disord. 2011 Jan;4(1):15-24. doi: 10.1177/1756285610392446.

16.

Activation of subthalamic neurons by contralateral subthalamic deep brain stimulation in Parkinson disease.

Walker HC, Watts RL, Schrandt CJ, Huang H, Guthrie SL, Guthrie BL, Montgomery EB Jr.

J Neurophysiol. 2011 Mar;105(3):1112-21. doi: 10.1152/jn.00266.2010. Epub 2010 Dec 22.

17.

Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements.

Cao X, Yasuda T, Uthayathas S, Watts RL, Mouradian MM, Mochizuki H, Papa SM.

J Neurosci. 2010 May 26;30(21):7335-43. doi: 10.1523/JNEUROSCI.0252-10.2010.

18.

Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.

Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL; 228 Study Investigators.

Mov Disord. 2010 May 15;25(7):858-66. doi: 10.1002/mds.22890.

PMID:
20461803
19.

Relief of acquired stuttering associated with Parkinson's disease by unilateral left subthalamic brain stimulation.

Walker HC, Phillips DE, Boswell DB, Guthrie BL, Guthrie SL, Nicholas AP, Montgomery EB, Watts RL.

J Speech Lang Hear Res. 2009 Dec;52(6):1652-7. doi: 10.1044/1092-4388(2009/08-0089).

PMID:
19951930
20.

Bilateral effects of unilateral subthalamic deep brain stimulation on Parkinson's disease at 1 year.

Walker HC, Watts RL, Guthrie S, Wang D, Guthrie BL.

Neurosurgery. 2009 Aug;65(2):302-9; discussion 309-10. doi: 10.1227/01.NEU.0000349764.34211.74.

PMID:
19625909
21.

Weight changes associated with unilateral STN DBS and advanced PD.

Walker HC, Lyerly M, Cutter G, Hagood J, Stover NP, Guthrie SL, Guthrie BL, Watts RL.

Parkinsonism Relat Disord. 2009 Nov;15(9):709-11. doi: 10.1016/j.parkreldis.2009.01.009. Epub 2009 Mar 9.

PMID:
19272829
22.

Liquid chromatography tandem mass spectrometry identification of proanthocyanidins in rat plasma after oral administration of grape seed extract.

Prasain JK, Peng N, Dai Y, Moore R, Arabshahi A, Wilson L, Barnes S, Michael Wyss J, Kim H, Watts RL.

Phytomedicine. 2009 Mar;16(2-3):233-43. doi: 10.1016/j.phymed.2008.08.006. Epub 2008 Dec 17.

23.

Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia.

Griffith HR, den Hollander JA, Okonkwo OC, O'Brien T, Watts RL, Marson DC.

Alzheimers Dement. 2008 Nov;4(6):421-7. doi: 10.1016/j.jalz.2008.04.008.

24.

The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.

Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Goldwurm S, Pezzoli G, Zini M, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Laramie JM, DeStefano AL, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.

BMC Med. 2008 Nov 5;6:32. doi: 10.1186/1741-7015-6-32.

25.

Corticobasal degeneration.

Stover NP, Walker HC, Watts RL.

Handb Clin Neurol. 2007;84:351-72. doi: 10.1016/S0072-9752(07)84048-6. No abstract available.

PMID:
18808957
26.

Medical decision-making capacity in cognitively impaired Parkinson's disease patients without dementia.

Martin RC, Okonkwo OC, Hill J, Griffith HR, Triebel K, Bartolucci A, Nicholas AP, Watts RL, Stover N, Harrell LE, Clark D, Marson DC.

Mov Disord. 2008 Oct 15;23(13):1867-74. doi: 10.1002/mds.22170.

27.

Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study.

McNicoll CF, Latourelle JC, MacDonald ME, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Saint-Hilaire MH, Massood T, Huskey KW, DeStefano AL, Gillis T, Mysore J, Goldwurm S, Pezzoli G, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-Hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.

Mov Disord. 2008 Aug 15;23(11):1596-601. doi: 10.1002/mds.22186.

28.

Spheramine for treatment of Parkinson's disease.

Stover NP, Watts RL.

Neurotherapeutics. 2008 Apr;5(2):252-9. doi: 10.1016/j.nurt.2008.02.006. Review.

29.

Brain N-acetylaspartate is reduced in Parkinson disease with dementia.

Griffith HR, den Hollander JA, Okonkwo OC, O'Brien T, Watts RL, Marson DC.

Alzheimer Dis Assoc Disord. 2008 Jan-Mar;22(1):54-60. doi: 10.1097/WAD.0b013e3181611011.

PMID:
18317247
30.

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.

Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE.

Mov Disord. 2007 Dec;22(16):2409-17.

PMID:
17894339
31.

Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease.

Jankovic J, Watts RL, Martin W, Boroojerdi B.

Arch Neurol. 2007 May;64(5):676-82.

PMID:
17502466
32.

A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease.

Warren L, Gibson R, Ishihara L, Elango R, Xue Z, Akkari A, Ragone L, Pahwa R, Jankovic J, Nance M, Freeman A, Watts RL, Hentati F.

Parkinsonism Relat Disord. 2008;14(1):77-80. Epub 2007 Apr 11.

PMID:
17433753
33.

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.

Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J.

Neurology. 2007 Jan 23;68(4):272-6. Epub 2007 Jan 3. Erratum in: Neurology. 2007 Aug 7;69(6):617. Neurology. 2007 Dec 4;69(23):2187.

PMID:
17202432
34.

Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study.

Wilk JB, Tobin JE, Suchowersky O, Shill HA, Klein C, Wooten GF, Lew MF, Mark MH, Guttman M, Watts RL, Singer C, Growdon JH, Latourelle JC, Saint-Hilaire MH, DeStefano AL, Prakash R, Williamson S, Berg CJ, Sun M, Goldwurm S, Pezzoli G, Racette BA, Perlmutter JS, Parsian A, Baker KB, Giroux ML, Litvan I, Pramstaller PP, Nicholson G, Burn DJ, Chinnery PF, Vieregge P, Slevin JT, Cambi F, MacDonald ME, Gusella JF, Myers RH, Golbe LI.

Neurology. 2006 Dec 26;67(12):2206-10.

PMID:
17190945
35.

Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families.

Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K, Wielinski C, Hunter C, Swartz JE, Elango R, Akkari PA, Leppert D, Surh L, Reeves KH, Thomas S, Ragone L, Hattori N, Pahwa R, Jankovic J, Nance M, Freeman A, Gouider-Khouja N, Kefi M, Zouari M, Ben Sassi S, Ben Yahmed S, El Euch-Fayeche G, Middleton L, Burn DJ, Watts RL, Hentati F.

Mov Disord. 2007 Jan;22(1):55-61.

PMID:
17115391
36.

Glutathione S-transferase polymorphisms and onset age in alpha-synuclein A53T mutant Parkinson's disease.

Golbe LI, Di Iorio G, Markopoulou K, Athanassiadou A, Papapetropoulos S, Watts RL, Vance JM, Bonifati V, Williams TA, Spychala JR, Stenroos ES, Johnson WG.

Am J Med Genet B Neuropsychiatr Genet. 2007 Mar 5;144B(2):254-8.

PMID:
17034008
37.

Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study.

Sun M, Latourelle JC, Wooten GF, Lew MF, Klein C, Shill HA, Golbe LI, Mark MH, Racette BA, Perlmutter JS, Parsian A, Guttman M, Nicholson G, Xu G, Wilk JB, Saint-Hilaire MH, DeStefano AL, Prakash R, Williamson S, Suchowersky O, Labelle N, Growdon JH, Singer C, Watts RL, Goldwurm S, Pezzoli G, Baker KB, Pramstaller PP, Burn DJ, Chinnery PF, Sherman S, Vieregge P, Litvan I, Gillis T, MacDonald ME, Myers RH, Gusella JF.

Arch Neurol. 2006 Jun;63(6):826-32.

PMID:
16769863
38.

Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease.

Stover NP, Bakay RA, Subramanian T, Raiser CD, Cornfeldt ML, Schweikert AW, Allen RC, Watts RL.

Arch Neurol. 2005 Dec;62(12):1833-7.

PMID:
16344341
39.

Occupation and parkinsonism in three movement disorders clinics.

Goldman SM, Tanner CM, Olanow CW, Watts RL, Field RD, Langston JW.

Neurology. 2005 Nov 8;65(9):1430-5. Epub 2005 Sep 14.

PMID:
16162857
40.

Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome.

Bliwise DL, Freeman A, Ingram CD, Rye DB, Chakravorty S, Watts RL.

Sleep Med. 2005 Mar;6(2):141-7.

PMID:
15716217
41.

Treatment of depression in Parkinson's disease.

Sawabini KA, Watts RL.

Parkinsonism Relat Disord. 2004 May;10 Suppl 1:S37-41. Review.

PMID:
15109585
42.

Ophthalmologic features of Parkinson's disease.

Biousse V, Skibell BC, Watts RL, Loupe DN, Drews-Botsch C, Newman NJ.

Neurology. 2004 Jan 27;62(2):177-80.

PMID:
14745050
43.

Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists.

Roth T, Rye DB, Borchert LD, Bartlett C, Bliwise DL, Cantor C, Gorell JM, Hubble JP, Musch B, Olanow CW, Pollak C, Stern MB, Watts RL.

Sleep Med. 2003 Jul;4(4):275-80.

PMID:
14592299
44.

Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease.

Li YJ, Oliveira SA, Xu P, Martin ER, Stenger JE, Scherzer CR, Hauser MA, Scott WK, Small GW, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Jankovic J, Goetz CG, Mastaglia F, Middleton LT, Roses AD, Saunders AM, Schmechel DE, Gullans SR, Haines JL, Gilbert JR, Vance JM, Pericak-Vance MA, Hulette C, Welsh-Bohmer KA.

Hum Mol Genet. 2003 Dec 15;12(24):3259-67. Epub 2003 Oct 21. Erratum in: Hum Mol Genet. 2004 Mar 1;13(5):573.

PMID:
14570706
45.

Determination of Dopamine Transporter Density(DAT) in Humans with an 18F Labeled Nortropane(FECNT) and PET.

Hoffman JM, Giroux M, Votaw JR, Kilts C, Martarello L, Votaw D, White M, Jones M, Watts RL, Goodman MM.

Clin Positron Imaging. 1998 Sep;1(4):257. No abstract available.

PMID:
14516580
46.

Stereotaxic intrastriatal implantation of human retinal pigment epithelial (hRPE) cells attached to gelatin microcarriers: a potential new cell therapy for Parkinson's disease.

Watts RL, Raiser CD, Stover NP, Cornfeldt ML, Schweikert AW, Allen RC, Subramanian T, Doudet D, Honey CR, Bakay RA.

J Neural Transm Suppl. 2003;(65):215-27. Review.

PMID:
12946059
47.

Association study of Parkin gene polymorphisms with idiopathic Parkinson disease.

Oliveira SA, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons KE, Pahwa R, Stern MB, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Scott BL, Goetz CG, Small GW, Mastaglia FL, Stajich JM, Zhang F, Booze MW, Reaves JA, Middleton LT, Haines JL, Pericak-Vance MA, Vance JM, Martin ER.

Arch Neurol. 2003 Jul;60(7):975-80.

PMID:
12873854
48.

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ; REAL-PET Study Group.

Ann Neurol. 2003 Jul;54(1):93-101.

PMID:
12838524
49.

Benefits and risks of pharmacological treatments for essential tremor.

Lyons KE, Pahwa R, Comella CL, Eisa MS, Elble RJ, Fahn S, Jankovic J, Juncos JL, Koller WC, Ondo WG, Sethi KD, Stern MB, Tanner CM, Tintner R, Watts RL.

Drug Saf. 2003;26(7):461-81. Review.

PMID:
12735785
50.

Parkin mutations and susceptibility alleles in late-onset Parkinson's disease.

Oliveira SA, Scott WK, Martin ER, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Ondo WG, Allen FH Jr, Scott BL, Goetz CG, Small GW, Mastaglia F, Stajich JM, Zhang F, Booze MW, Winn MP, Middleton LT, Haines JL, Pericak-Vance MA, Vance JM.

Ann Neurol. 2003 May;53(5):624-9.

PMID:
12730996

Supplemental Content

Loading ...
Support Center